Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101

Rhea-AI Summary

Xenon Pharmaceuticals (Nasdaq:XENE) will host a conference call and webcast on October 4, 2021, at 7:30 AM ET to discuss topline results from the XEN1101 Phase 2b “X-TOLE” clinical trial. Investors can join the conference call by dialing (855) 779-9075 in the U.S. or (631) 485-4866 internationally, using conference ID number 4481713. The call will be available on the Xenon website for replay after the event. Xenon is focused on developing innovative treatments for neurological disorders, particularly epilepsy.

Positive

• Upcoming presentation of topline results from XEN1101 Phase 2b X-TOLE trial.
• Demonstrates ongoing commitment to improving therapies for neurological disorders.

Negative

• None.

BURNABY, British Columbia, Oct. 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Xenon management will host a conference call and webcast to discuss topline results from the XEN1101 Phase 2b “X-TOLE” clinical trial on Monday, October 4, 2021 at 7:30 am Eastern Time.

• A conference call and webcast with slides will be broadcast live on the Investors section of the Xenon website. To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 4481713.
  

The above listed dates and times are subject to change. When available, webcasts will be posted for replay following the event.

About Xenon Pharmaceuticals Inc.

We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Media / Investor Contacts:
Maria McClean / Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604-484-3353 / 778-999-5634
Email: investors@xenon-pharma.com

FAQ

What is the purpose of the XEN1101 Phase 2b X-TOLE clinical trial?

The XEN1101 Phase 2b X-TOLE clinical trial aims to evaluate the efficacy and safety of XEN1101 for treating epilepsy.

When will the XEN1101 trial results be announced?

The topline results from the XEN1101 trial will be discussed in a conference call on October 4, 2021.

How can I participate in the Xenon Pharmaceuticals conference call?

To participate in the conference call, dial (855) 779-9075 in the U.S. or (631) 485-4866 internationally, using conference ID number 4481713.

Where can I find the webcast of the Xenon Pharmaceuticals event?

The webcast will be available in the Investors section of the Xenon Pharmaceuticals website.

What areas is Xenon Pharmaceuticals focusing on?

Xenon Pharmaceuticals is focused on developing innovative therapeutics for neurological disorders, with a particular emphasis on epilepsy.